The University of Virginia is conducting a clinical research study for adults ages 18 and over, who fall into one of the following groups:
o Group A (cutaneous/subcutaneous) will include the following tumor-specific cohorts:
? Squamous cell carcinomas of the head and neck (SCCHN)
? Dermatological
? Genitourinary/gynecological
? Gastrointestinal
? Other cutaneous/subcutaneously accessible solid tumors
o Group B: visceral lesions accessible by ultrasound/CT guidance

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have endometrial cancer. The purpose of this study is to find out if we can lower the chance of your endometrial cancer growing or spreading by adding a new immunotherapy drug, pembrolizumab, to the usual combination of chemotherapy drugs, paclitaxel and carboplatin.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma. This study is being done to answer the following questions:

1. What are the good and bad effects of using usual chemotherapy and radiation plus the immunotherapy, nivolumab, before standard surgery for your condition?
2. What are the good and bad effects of adding the immunotherapy nivolumab versus adding nivolumab and ipilimumab after standard surgery for your condition?

The University of Virginia Cancer Center is conducting a clinical research study for adult patients with mantle cell lymphoma ages 18 and over who have achieved an excellent minimal residual disease-negative first complete remission. The purpose of this research study is to determine whether an autotransplant improves survival in MCL patients who have achieved an excellent (MRD-negative) first complete remission (CR). This research study has three study groups and patients who are MRD-negative will be randomly assigned to group 1 or 2 as below.

The Department of Radiation Oncology seeks men ages 18 and older with prostate cancer for a research study. The purpose of the study is to test whether a combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment and external beam radiation therapy (EBRT) treatments lead to less side effects than similar treatments that don’t use an MRI during brachytherapy. This study is also looking at patient outcomes, quality of life and overall survival for patients receiving this treatment.

The Department of Radiation Oncology seeks men ages 18 and older with locally recurrent prostate cancer for a research study. The purpose of the study is to out if having brachytherapy treatment (internal radiation procedure), in one or two treatments, is safe and effective. This study is also looking at patient outcomes, quality of life and overall survival for patients receiving this treatment.

You may be eligible for this study if you have been diagnosed with locally recurrent prostate cancer previously treated with radiation and plan on receiving brachytherapy for treatment.

The Department of Radiation Oncology seeks adults ages 18 and older with gynecological cancers for a research study. The purpose of the study is to determine if tumor cells or tumor materials circulating in the blood can be used as a tool in the future to help guide cancer treatment decisions during or after radiation with or without chemotherapy.

You may be eligible for this study if you have been diagnosed with gynecological cancer -such as cervical, vaginal vulvar or endometrial and plan on receiving radiation therapy as a part of your definitive treatment plan.

The UVA Allergy and Immunology laboratory is seeking adults, ages 18 and over, from the Charlottesville community, to investigate the immune response to COVID-19 Vaccines. The goal will be to use a novel quantitative test to measure antibody levels before and after the "booster" vaccination (for example, the second dose after a Johnson & Johnson vaccine, or the third dose after a Pfizer/Moderna COVID-19 vaccine).

Dr. Kari Ring and Dr. Susan Modesitt are Co-Directors of UVA’s High Risk Breast and Ovarian Cancer clinic that was established in 2007 to provide individualized genetic risk assessment, customized cancer screening and cancer risk reducing medications or surgeries to women at high risk to develop cancer. Women with BRCA1 mutations have an extremely high risk of developing ovarian cancer but it is thought that the majority of ovarian cancers may start in the fallopian tubes.

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have nonsquamous non-small cell lung cancer. The purpose of this study to evaluate an immunotherapy drug (pembrolizumab) alone or in combination with chemotherapy (carboplatin and pemetrexed) in patients with nonsquamous non-small cell lung cancer. The safety and effects of the experimental drug alone and in combination with chemotherapy will be evaluated for this study.